期刊文献+

Protective effects of docosahexaenoic acid against non-alcoholic hepatic steatosis through activating of JAK2/STAT3 signaling pathway 被引量:1

在线阅读 下载PDF
导出
摘要 Non-alcoholic fatty liver disease is the most common cause of hepatic dysfunction.In the present study,human normal hepatocyte L02 cells were treated with 50%fetal bovine serum to induce the formation of hepatic steatosis in vitro,and then the cells were treated with docosahexaenoic acid to investigate its protective effect on Non-alcoholic fatty liver disease.Our results showed that 50%of fetal bovine serum significantly induced intracellular lipid accumulation and hepatocyte fatty degeneration within 48 h.The expression level of adipose formation-related genes was significantly up-regulated,such as PPARγ,C/EBPαand SREBP-1;meanwhile,the content of cellular total lipid,total cholesterol and triglycerides were significantly increased after 50%fetal bovine serum treatment.Interestingly,docosahexaenoic acid treatment could inhibit FBS-induced intracellular lipid accumulation in L02 cells and the expression of lipogenic genes.Moreover,docosahexaenoic acid treatment could reduce hepatic steatosis-induced oxidative stress and endoplasmic reticulum stress response,and these responses were shown by the modification of antioxidant enzyme activities and GRP78,CHOP expression.In addition,the results showed that docosahexaenoic acid can activate the JAK2/STAT3 signaling pathway in fatty liver L02 cell;inhibition of JAK2/STAT3 signaling pathway by WP1066 abolished the beneficial effects of docosahexaenoic acid on hepatic steatosis accompanied with the increased expression of lipogenic genes and endoplasmic reticulum stress response.Above all,the present study showed that docosahexaenoic acid can alleviate non-alcoholic hepatic steatosis by activating JAK2/STAT3 signaling pathway.
出处 《BIOCELL》 SCIE 2021年第2期307-316,共10页 生物细胞(英文)
基金 This work was supported by the Natural Science Foundation of Jiangsu Province[Grant No.BK20190254] the China Postdoctoral Science Foundation[Grant No.2019M651755].
  • 相关文献

参考文献1

二级参考文献10

  • 1Otogawa K,Kawada N.Rabbit model for the study of human NASH.Nippon Rinsho,2006,64:1043-1047.
  • 2Lieber CS,Leo MA,Mak KM,et al.Model of nonalcoholic steatohepatitis.Am J Clin Nutr,2004,79:502-509.
  • 3Donato MT,Lahoz A,Jiménez N,et al.Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts.Drug Metab.Dispos,2006,34:1556-1562.
  • 4Cupp D,Kampf JP,Kleinfeld AM.Fatty acid-albumin complexes and the determination of the transport of long chain free fatty acids across membranes.Biochemistry,2004,43:4473-4481.
  • 5Gasbatrini G,Vero V,Miele L,et al.Nonalcoholic fatty liver disease:defining a common problem.Eur Rev Med Pharmacol.Sci,2005,9:253-259.
  • 6Bradbury MW.Lipid metabolism and liver inflammation.Ⅰ.Hepatic fatty acid uptake:possible role in steatosis,Am J Physiol Gastrointest Liver Physiol,2006,290:G194-198.
  • 7Araya J,Rodrigo R,Videla LA,et al.Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relalion to hepatic steatosis in patients with non-alcoholic fatty liver disease.Clin Sci(Lond),2004,106:635-643.
  • 8Gómez-Lechón MJ,Donato MT,Martínez-Romero A,et al.A human hepatocellular in vitro model to investigate steatosis.Chem Biol Interact,2007,165:106-116.
  • 9Feldstein AE,Werneburg NW,Canbay A,et al.Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway.Hepatology,2004,40:185-194.
  • 10Medina J,Fernandez-Salazar LI,Garcia-Buey L,et al.Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.Diabetes Care,2004,27:2057-2066.

共引文献3

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部